The objective of the Oklahoma Adult Division of the Southwest Oncology Group is to provide an investigational framework for the management of patients with cancer at the Oklahoma University Health Sciences Center. During 1982, a new Section of Medical Oncology was established within the Department of Medicine and new faculty recruited at the University both in Medical and Surgical disciplines committed to developing a broad program of basic oncology and clinical trial studies in patients with cancer. Emphasis will be placed on interdisciplinary approaches for cooperative therapeutic research.
THe specific aims for the five year grant period include 1) Development of pilot protocols at the local level for subsequent group consideration. Particular emphasis will be placed in areas of allogeneic and autologous bone marrow transplantation for extended chemotherapy, and irradiation treatment of leukemia and selected solid tumors. 2) Accrual of patients to protocols generated by the Southwest Oncology Group disease committees. 3) Increased conceptual contribution to specific disease committees of the Southwest Oncology Group by virtue of new faculty recruitment in areas of marrow transplantation, breast, lung, lymphoma, GI, urologic, and head and neck malignancies. 4) Service contribution to the group in methodologies including cryopreservation techniques, cell culture, monoclonal antibody technology and granulocyte transfusion support. The accrual of patients for studies is based primarily on participation of Health Sciences Center facilities including The University of Oklahoma Hospital, Veterans Administration Hospital, Oklahoma Research Foundation Oncology Clinic and Presbyterian Hospital. In addition members in other community hospitals are expected to participate in a vigorous manner. Basic scientific expertise contributing to development of new initiatives stems from recruitment of faculty including the PI engaged in laboratory studies of tumor immunology and hematopoietic support techniques during periods of marrow failure.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA035995-02
Application #
3557834
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1984-02-01
Project End
1987-12-31
Budget Start
1985-01-01
Budget End
1985-12-31
Support Year
2
Fiscal Year
1985
Total Cost
Indirect Cost
Name
University of Oklahoma Health Sciences Center
Department
Type
Schools of Medicine
DUNS #
937727907
City
Oklahoma City
State
OK
Country
United States
Zip Code
73117
Rivkin, Saul E; Green, Stephanie J; Lew, Danika et al. (2003) Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of Cancer 97:21-9
Taylor, Sarah A; Rankin, Cathryn; Townsend, Jeannette J et al. (2002) Phase II trial of amonafide in central nervous system tumors: a Southwest Oncology Group study. Invest New Drugs 20:113-5
Grozea, P N; Crowley, J J; Canfield, V A et al. (1997) Teniposide (VM-26) as a single drug treatment for patients with extensive small cell lung carcinoma: a Phase II study of the Southwest Oncology Group. Cancer 80:1029-33
Saez, R; Dahlberg, S; Appelbaum, F R et al. (1994) Autologous bone marrow transplantation in adults with non-Hodgkin's lymphoma: a Southwest Oncology Group study. Hematol Oncol 12:75-85
Kuebler, J P; Metch, B; Schuller, D E et al. (1991) Phase II study of fazarabine in advanced head and neck cancer. A Southwest Oncology Group study. Invest New Drugs 9:373-4
Kuebler, J P; Goodman, P J; Brown, T D et al. (1990) Phase II study of continuous infusion recombinant gamma interferon in renal carcinoma. A Southwest Oncology Group study. Invest New Drugs 8:307-9
Hussein, K K; Dahlberg, S; Head, D et al. (1989) Treatment of acute lymphoblastic leukemia in adults with intensive induction, consolidation, and maintenance chemotherapy. Blood 73:57-63
Miller, T P; Vance, R B; Ahmann, F R et al. (1986) Extensive non-small cell lung cancer treated with mitomycin, cisplatin, and vindesine (MiPE): a Southwest Oncology Group Study. Cancer Treat Rep 70:1101-4